{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jiang X"],"funding":["National Health Commission project","Science and Technology Department of Henan Province","medical science and technology project of Henan Province"],"pagination":["272"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11368034"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(1)"],"pubmed_abstract":["<h4>Background</h4>Mesenchymal stem cells (MSCs) possess powerful immunomodulatory ability. This study aimed to assess the efficacy and safety of human umbilical cord-derived mesenchymal stem cells (UMSCs) in patients with ulcerative colitis (UC) and to explore the potential mechanisms.<h4>Methods</h4>This prospective, self-controlled clinical study was conducted at Henan Provincial People's Hospital. Patients with moderate-to-severe active UC, unresponsive to traditional drugs were continuously enrolled from September 2018 to March 2023. UMSCs were administered intravenously monthly for two months at a cell dosage of 1 × 10<sup>6</sup> per kg. The primary outcome was a clinical response at 2 months. The levels of cytokines and progerin in the plasma of the patients were analyzed using enz"],"journal":["Stem cell research & therapy"],"pubmed_title":["Umbilical cord mesenchymal stem cells in ulcerative colitis treatment: efficacy and possible mechanisms."],"pmcid":["PMC11368034"],"funding_grant_id":["SBGJ202001002","CMR-20180615-1001","212102310203"],"pubmed_authors":["Ding H","Liu M","Liang Y","Zhang H","Huang H","Bai Y","Han S","Yue H","Shi Y","Li X","Li Y","Yang Z","Cai C","Li Z","Jiang X","Peng C","Luo X","Zhang B"],"additional_accession":[]},"is_claimable":false,"name":"Umbilical cord mesenchymal stem cells in ulcerative colitis treatment: efficacy and possible mechanisms.","description":"<h4>Background</h4>Mesenchymal stem cells (MSCs) possess powerful immunomodulatory ability. This study aimed to assess the efficacy and safety of human umbilical cord-derived mesenchymal stem cells (UMSCs) in patients with ulcerative colitis (UC) and to explore the potential mechanisms.<h4>Methods</h4>This prospective, self-controlled clinical study was conducted at Henan Provincial People's Hospital. Patients with moderate-to-severe active UC, unresponsive to traditional drugs were continuously enrolled from September 2018 to March 2023. UMSCs were administered intravenously monthly for two months at a cell dosage of 1 × 10<sup>6</sup> per kg. The primary outcome was a clinical response at 2 months. The levels of cytokines and progerin in the plasma of the patients were analyzed using enz","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2025-05-31T22:19:01.016Z","creation":"2024-11-09T17:36:09.027Z"},"accession":"S-EPMC11368034","cross_references":{"pubmed":["39218946"],"doi":["10.1186/s13287-024-03878-y"]}}